Cargando…
Intranasal GSK2245035, a Toll-like receptor 7 agonist, does not attenuate the allergen-induced asthmatic response in a randomized, double-blind, placebo-controlled experimental medicine study
BACKGROUND: Allergic asthma is a heterogenous disorder predominantly driven by a type 2 inflammatory response to aeroallergens. Therapeutic modulation to rebalance these type 2 responses may offer clinical benefit for allergic respiratory inflammatory diseases, with the potential for disease modific...
Autores principales: | Siddall, Hilary, Quint, Diana, Pandya, Hitesh, Powley, Will, Shabbir, Shaila, Hohlfeld, Jens M., Singh, Dave, Lee, Laurie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7652256/ https://www.ncbi.nlm.nih.gov/pubmed/33166307 http://dx.doi.org/10.1371/journal.pone.0240964 |
Ejemplares similares
-
Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy
por: Kirtland, Max E., et al.
Publicado: (2020) -
Impact of endobronchial allergen provocation on macrophage phenotype in asthmatics
por: Winkler, Carla, et al.
Publicado: (2014) -
Inhibition of the early asthmatic response to inhaled allergen by the 5-lipoxygenase activating protein inhibitor GSK2190915: a dose–response study
por: Singh, Dave, et al.
Publicado: (2013) -
House Dust Mite Allergen Regulates Constitutive Apoptosis of Normal and Asthmatic Neutrophils via Toll-Like Receptor 4
por: Kim, Do Hyung, et al.
Publicado: (2015) -
Clinical and Laboratory Studies of the Fate of Intranasal Allergen
por: Rimmer, Janet, et al.
Publicado: (2015)